Pursuing Breakthroughs in the Treatment of NASH
Pfizer is building a drug research and development program that addresses complications such as the buildup of fat, inflammation, fibrosis and metabolic dysfunction that can lead to nonalcoholic steatohepatitis (NASH).
NASH is a progressive liver disease that affects an estimated 3 to 5 percent of the global adult population. There are no approved medicines and it is expected to be the leading cause of liver transplants within the next decade. Pfizer is building a robust drug research and development program that targets NASH through multiple, diverse pathways of the disease. Our approach is comprehensive - to address complications that lead to NASH, like the buildup of liver fat and metabolic dysfunction - with the goal of improving liver inflammation and fibrosis. Pfizer entered into a non-exclusive clinical development agreement with Novartis to investigate one or more combinations of our three clinical assets in development for the treatment of NASH with Novartis's tropifex.
Ian Read: Contributions to Improving Human Health
Albert Bourla: Breakthroughs that Change Patients' Lives
Ushering in a New Era of Pfizer R&D Productivity
Advancing Our Leading JAK Science
Overcoming Therapy-Resistant Disease
Tackling Respiratory Syncytial Virus (RSV) Through Breakthrough Science and Technology
Catalyzing Innovations in Global Health
Contributing to the UN Sustainable Development Goals
Supporting Digital Health Start-Ups
Improving the Health of Women and Their Families